类风湿关节炎患者外周血IL-23/IL-17轴与病情的关系及对骨破坏进展的预测价值

doi:10.3969/j.issn.1006-6233.2024.10.022

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1352 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the relationship between the interleukin-23 (IL-23)/interleukin-17 (IL-17) axis in the peripheral blood of patients with rheumatoid arthritis (RA) and disease activity, and its predictive value for the progression of bone destruction. Methods: A total of 118 RA patients were enrolled between May 2022 and October 2023. They were divided into mild, moderate, and severe disease activity groups according to the Disease Activity Score 28 (DAS28) and received symptomatic treatment based on their condition. Patients were followed up for 6 months, and were further divided into a progression group (27 cases) and a non-progression group (91 cases) based on the presence of bone destruction progression. Fasting venous blood (3 mL) was collected from each patient on the morning after admission, and the levels of IL-23/IL-17 axis factors [IL-23, IL-17, interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)] were measured using enzyme-linked immunosorbent assay (ELISA). The correlation between IL-23/IL-17 axis factors and disease activity was analyzed, and the predictive value of these factors for bone destruction progression was evaluated. Results: The disease course and disease activity in the progression group were significantly higher than those in the non-progression group (P<0.05). The levels of IL-23, IL-17, IL-1β, IL-6, and TNF-α in the peripheral blood of the progression group [(192.38±48.72) pg/mL, (31.13±7.24) pg/mL, (88.71±29.10) pg/mL, (18.59±4.21) pg/mL, (180.31±41.57) ng/L] were higher than those in the non-progression group [(149.07±42.15) pg/mL, (25.04±5.39) pg/mL, (56.92±16.52) pg/mL, (15.16±3.44) pg/mL, (142.59±36.62) ng/L] (P<0.05). The levels of IL-23, IL-17, IL-1β, IL-6, and TNF-α in the peripheral blood showed a progressive increase from patients with mild to moderate to severe disease activity (P<0.05). The levels of IL-23, IL-17, IL-1β, IL-6, and TNF-α were positively correlated with disease activity (P<0.05). Partial correlation analysis showed that after excluding the influence of disease course and disease activity, IL-23, IL-17, IL-1β, IL-6, and TNF-α remained significantly correlated with the progression of bone destruction in RA patients (P<0.05). The area under the curve (AUC) values for IL-23, IL-17, IL-1β, IL-6, and TNF-α in predicting the progression of bone destruction in RA patients were 0.807, 0.804, 0.793, 0.792, and 0.794, with sensitivities of 81.48%, 74.07%, 74.07%, 85.19%, and 66.67%, and specificities of 70.33%, 75.82%, 73.63%, 71.43%, and 80.22%, respectively. The combined prediction of bone destruction progression had an AUC of 0.931, with a sensitivity of 85.19% and specificity of 87.91%, which was significantly superior to the individual predictions (Z=2.715, 2.803, 3.026, 3.114, 2.984, all P<0.001). Conclusion: The IL-23/IL-17 axis in peripheral blood is significantly associated with disease activity in RA patients and has a reliable predictive value for the progression of bone destruction.

Key words： Rheumatoid Arthritis IL-23/IL-17 Axis Dsease activity Correlation Bone destruction progression Predictive value

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Zhongshuang
	ZHU Honghong
	LIU Ying

Cite this article:

MA Zhongshuang,ZHU Honghong,LIU Ying. The Relationship between IL-23/IL-17 Axis in Peripheral Blood and Disease Activity in Patients with Rheumatoid Arthritis and Its Predictive Value for Bone Destruction Progression[J]. HeBei Med, 2024, 30(10): 1700-1704.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.10.022 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I10/1700

[1] Radu AF,Bungau SG.Management of rheumatoid arthritis: an overview[J].Cells,2021,10(11):2857.
[2] Cush JJ.Rheumatoid arthritis: early diagnosis and treatment[J].Rheum Dis Clin North Am,2022,48(2):537-547.
[3] Guagnano MT,D'angelo C,Caniglia D,et al.Improvement of inflammation and pain after three months' exclusion diet in rheumatoid arthritis patients[J].Nutrients,2021,13(10):3535.
[4] Sui AL,Chen XP,Yao YY,et al.The IL-23/IL-17 axis promotes the formation of retinal neovascularization by activating the NLRP3 inflammasome in macrophages in an experimental retinopathy mouse model[J].Immunology,2021,164(4):803-816.
[5] Ten Bergen LL,Petrovic A,Krogh Aarebrot A,et al.The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment[J].Scand Immunol,2020,92(4):12946.
[6] 中华医学会风湿病学分会.类风湿关节炎诊断及治疗指南[J].中华风湿病学杂志,2010,14(4):265-270.
[7] 栾仲秋,李秋红,王继坤,等.类风湿性关节炎患者IL-1β、IL-6、IL-17、IL-23和IL-33炎性相关因子变化的临床意义[J].解放军预防医学杂志,2019,37(3):64-65,68.
[8] Koper-Lenkiewicz OM,Sutkowska K,Wawrusiewicz-Kurylonek N,et al.Proinflammatory cytokines (IL-1,-6,-8,-15,-17,-18,-23,TNF-α) single nucleotide polymorphisms in rheumatoid arthritis-A literature review[J].Int Mol Sci,2022,23(4):2106.
[9] El-Tanbouly GS,Abdelrahman RS.Novel anti-arthritic mechanisms of trans-cinnamaldehyde against complete Freund's adjuvant-induced arthritis in mice: involvement of NF-кB/TNF-α and IL-6/IL-23/ IL-17 pathways in the immuno-inflammatory responses[J].Inflammopharmacology,2022,30(5):1769-1780.
[10] Rodrfguez-Montano R,Bernard-Medina AG,Oregon-Romero E,et al.IL-23/IL-17 axis and soluble receptors isoforms sIL-23R and sIL-17RA in patients with rheumatoid arthritis-presenting periodontitis[J].Clin Lab Anal,2021,35(9):23963.
[11] Selmov P,Karalilova R,Damjanovska L,et al.Rheumatoid arthritis and the proinflammatory cytokine IL-17[J].Folia Med (Plovdiv),2023,65(1):53-59.
[12] Byravan S,Samarasinghe H,Yuan JSJ,et al.From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis[J].Expert Opin Investig Drugs,2024,33(6):591-600.
[13] Zhang L,Mao DM,Zhang Q.Correlation between sarcopenia and nailfold microcirculation, serum 25-hydroxycholecalciferol (vitamin D3) and IL-17 levels in female patients with rheumatoid arthritis[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2021,165(3):264-269.